Skip to content

A study on the application of food frequency questionnaire (FFQ) in patients with type 2 diabetes mellitus

A study on the application of food frequency questionnaire (FFQ) in patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040373
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, non-alcoholic fatty liver disease

Interventions

case series:none

Sponsors

School of Nursing, Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: NAFLD: 1. According to the Chinese Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (2010 Revised Edition): 1) no history of alcohol consumption or less than 140 g/week of alcohol consumption (female =11.1mmol/L(200mg/d)L); (2) fasting blood glucose (FPG) >=7.0 mmol /L; (3) glucose load after 2h blood glucose (2h PG) < 11.1mmol /L; (4) Patients without typical symptoms of diabetes.

Exclusion criteria

Exclusion criteria: 1. History of Alcohol intake>20g/d; 2. Co-existing of other liver diseases, such as viral, drug-induced, auto-immune hepatitis and so on; 3. Suspicion of liver cirrhosis or liver cancer; 4. Co-existing of other severe systematic disease or infectious disease, such as malignant neoplasm, severe cardiopulmonary disease, neurological disorders, HIV infection and so on; 5. Unable to control diet or to conduct aerobic exercise; 6. Currently pregnant, breastfeeding, pregnancy anticipated during study or planning to be conceive; 7. Co-existing of mental disorders or severe neurosis, or unable to express symptoms subjectively and hindering connection and cooperation with researchers because of dysgnosia or aphasis. 8. Exclude patients with type 1 diabetes 9. Exclude long-term insulin therapy and patients with suspicious autoimmune diseases

Design outcomes

Primary

MeasureTime frame
liver function;blood lipids;Liver fat content(Quantitative ultrasound);blood inflammatory markers;Fasting Blood Glucose;Hemoglobin A1c (HbA1c);

Countries

China

Contacts

Public ContactYinji Liang

School of Nursing, Jinan University

tlyj@hotmail.com+86 13751775188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026